Tarsier Pharma

Israel-based Phase 3 ocular diseases biotech Tarsier Pharma files for a $35 million US IPO IPO Overview Tarsier Pharma, an Israel-based Phase 3 biotech developing steroid-free therapies for ocular diseases, filed on Tuesday with the SEC to raise up to... Read more